Silver Nanogap Shell SERS Immunoassay for Alzheimer's Biomarker Detection

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current diagnostic methods for Alzheimer's disease are invasive, expensive, and limited in sensitivity, unable to detect multiple biomarkers simultaneously, leading to late and inaccurate diagnoses.

Innovation Solution

A silver nanogap shell-based SERS immunoassay using antibodies specific for Aβ40 and Aβ42, immobilized on a substrate such as a magnetic bead, enables non-invasive detection of these biomarkers in blood with high sensitivity by forming a sandwich complex and measuring Raman signals to diagnose Alzheimer's disease and differentiate it from mild cognitive impairment.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Measurement precision

If SERS-based diagnostic method is used, then sensitivity and multiplexed detection capability are improved, but the method is limited to detection of a single target and sensitivity remains very low

Engineering Contradiction:

Improvedetection sensitivityVSAvoidmultiplexed detection capability

Core Design Contradiction:

Measurement precisionVSAdaptability or versatility

Solution Approach 1:

The invention divides the detection system into multiple specialized probes, each functionalized with specific antibodies for different biomarkers (Aβ40, Aβ42, tau). Each probe segment is optimized for detecting a specific target, allowing simultaneous multiplexed detection while maintaining high sensitivity for each individual biomarker through SERS signal amplification

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The silver nanogap shell structure serves as a universal platform that can be functionalized with various antibodies to detect multiple different biomarkers. The core SERS detection mechanism remains the same while the antibody coating provides specific recognition for different targets, enabling one system to perform multiple detection functions simultaneously

Inventive Principle:

Principle #6Universality (Multi-functionality)

2Measurement precision

If brain imaging techniques and invasive cerebrospinal fluid sampling are used, then diagnosis accuracy is improved, but patient suffering and cost increase

Engineering Contradiction:

Improvediagnosis accuracyVSAvoidpatient suffering and invasiveness

Core Design Contradiction:

Measurement precisionVSObject-affected harmful factors

Solution Approach 1:

The invention uses blood as an intermediary fluid that can be sampled non-invasively or minimally invasively. Blood contains biomarkers that correlate with brain pathology, serving as a surrogate for direct brain imaging or CSF sampling. The SERS probes detect these biomarkers in blood, providing accurate diagnosis without requiring invasive procedures

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The invention replaces expensive brain imaging equipment (PET scanners) with a simple optical detection system based on SERS spectroscopy. The silver nanogap shells provide extreme signal enhancement, allowing detection of trace biomarkers in blood using portable Raman spectrometers instead of expensive and complex imaging machinery

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

3Reliability

If existing diagnostic technologies are used, then diagnosis can be performed, but only after symptoms have progressed considerably and only single biomarker tracing is possible

Engineering Contradiction:

Improvediagnosis timingVSAvoidbiomarker tracing capability

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The invention enables detection of biomarkers at very early stages of disease, before significant symptoms appear. The ultra-sensitive SERS detection can identify trace amounts of Aβ42 and tau biomarkers in blood during the pre-symptomatic phase, allowing preliminary diagnosis and early intervention before neurological damage becomes apparent

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The invention combines detection of multiple biomarkers (Aβ40, Aβ42, tau) into a single integrated assay using a panel of SERS probes. By measuring the ratio of Aβ42 to Aβ40 along with tau levels simultaneously in one blood sample, the system provides comprehensive diagnostic information that improves reliability and enables earlier more accurate diagnosis than single biomarker methods

Inventive Principle:

Principle #5Merging (Combining)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The method allows for simultaneous detection of Aβ40 and Aβ42 with sensitivity below 1 pg/mL, enabling early and accurate diagnosis of Alzheimer's disease and differential diagnosis from mild cognitive impairment through a non-invasive blood test, overcoming the limitations of existing technologies.

Implementation Method 1

silver nanogap shell-based SERS immunoassay

Methodology Applied

Scientific EffectSurface-enhanced Raman scattering (SERS):

Implementation Method 2

the substrate may include a magnetic bead and the silver nanogap shell may be immobilized using the magnetic bead

Methodology Applied

Scientific EffectMagnetic property: Magnetism

Data Source

PatentUS20220155325A1Method for diagnosing alzheimer's disease using silver nanogap shell

Publication Date: 2022.05.19 CARBOEXPERT INC

AI summary

The present disclosure relates to a method for diagnosing Alzheimer's disease (AD) using a silver nanogap shell, which enables non-invasive early diagnosis of AD via multiplexed detection of a plurality of Alzheimer's disease target biomarkers with high sensitivity.